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Navneet S. Majhail, MD, MS,1 Tejo R. Challa, MD,1 Daniel A. Mulrooney, MD, MS,1
K. Scott Baker, MD, MS,2 Linda J. Burns, MD1Hypertension and diabetes are frequent early complications of allogeneic hematopoietic cell transplantation
(HCT); however, their long-term outcomes are not well known.We conducted a retrospective cohort study
to describe the risk factors and natural history of post-HCT hypertension and diabetes in 180 consecutive
adult (n5 106) and pediatric (n5 74) allogeneic HCTrecipients from 2003-2005 who had survived for 1 year
post-HCT. The pediatric patients were less likely than the adult patients to have pre-HCT hypertension and
diabetes, smoking history, or high-risk disease and more likely to receive myeloablative (MA) conditioning.
All patients were followed until at least 2 years post-HCT; of these 1-year survivors, 156 (87%) were alive at
2 years. Acute or chronic graft-versus-host disease (aGVHD, cGVHD) occurred in 118 (66%) patients; of
these, 24% received cyclosporine (CsA) for .12 months and 47% received prednisone for .12 months.
Within 2 years post-HCT, 126 (70%) had hypertension and 54 (30%) had diabetes. Rates were similar for
the adult recipients (hypertension, 68%; diabetes, 30%) and the pediatric recipients (hypertension, 73%; di-
abetes, 30%). At 2 years post-HCT, in the patients with hypertension, hypertension had not resolved in 34%,
and among patients with diabetes, diabetes had not resolved in 32%. On multivariate analyses, exposure to
CsA increased the risk of developing hypertension post-HCT (relative risk, 1.6; 95% confidence interval [CI],
1.1-2.5; P 5 .03), but did not affect its persistence at 2 years. Exposure to high-dose corticosteroids (cumu-
lative prednisone dose of. 0.25 mg/kg/day) increased the likelihood of developing diabetes (relative risk, 3.6;
95%CI, 1.7-7.5; P\.01) and for having persistent diabetes at 2 years post-HCT (relative risk, 4.1; 95%CI, 1.0-
18.2; P 5 .05). Hypertension and diabetes are frequent early complications of allogeneic HCT, but subse-
quently resolve in a large proportion of recipients in the first 2 years after transplantation. Continued mon-
itoring and treatment of hypertension and diabetes is necessary in allogeneic HCT survivors, especially in
those exposed to high doses of corticosteroids.
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Allogeneic hematopoietic cell transplantation
(HCT) can be associated with significant early and
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lation, and both pediatric and adult long-term
allogeneic HCT survivors are at risk for developing
metabolic syndrome, hypertension, diabetes mellitus,
premature arterial cardiovascular events, and conges-
tive heart failure [1-8]. Hypertension and diabetes
frequently occur in the early posttransplantation
period and have a variable clinical course. Over time,
these disorders can improve and even resolve in some
patients, but can persist in others. Although they are
not life-threatening, they can contribute to the mor-
bidity of transplantation and are potential risk factors
for development of cardiovascular late complications.
Calcineurin inhibitor and corticosteroid exposure are
thought to increase the risk of hypertension and
diabetes, but this has not yet been studied systemati-
cally. A better understanding of the natural history of
post-HCT hypertension and diabetes and of the risk
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tence is important for developing strategies for their
screening, prevention, and early management. We
conducted a retrospective cohort study to describe
the natural history of early-onset hypertension and
diabetes in allogeneic HCT survivors.METHODS
Patient Selection and Follow-Up
Our single-institution study included consecutive
adult (aged$ 18 years) and pediatric (aged\18 years)
allogeneic HCT recipients who underwent transplan-
tation between 2003 and 2005 and survived for at least
1 year post-HCT. Because we primarily wanted to
study the natural history of post-HCT hypertension
and diabetes mellitus along with risk factors for their
persistence in long-term HCT survivors, patients
who died within the first year post-HCT were
excluded. Recipients of both myeloablative (MA) and
nonmyeloablative (NMA) preparative regimens were
eligible, however, recipients of multiple HCTs (n 5
12) were excluded. Patient-, disease-, and transplant-
related information was obtained from the University
of Minnesota Blood and Marrow Transplant database,
which prospectively collects such data for all patients
undergoing HCT at our institution. Additional data,
including details of hypertension and diabetes, labora-
tory investigations, and duration and dose of immuno-
suppressive therapy, were abstracted from our
institution’s electronic patient medical records. All
patients underwent transplantation on protocols
approved by our institutional review board.
All patients undergoing HCT at our institution
receive post-HCT care exclusively within our Blood
and Marrow Transplant Program up to at least day
100. Subsequently, all patients return for follow-up
at 6, 9, 12, 18 and 24 months post-HCT. Assessments
at these time points include blood pressure and fasting
plasma glucose measurements. Patient medications are
also reviewed and recorded. Additional follow-up, as
clinically indicated (eg, for management of chronic
graft-versus-host disease [cGVHD]), is at the discre-
tion of the patient’s transplantation physician.Conditioning Regimens and Supportive Care
The MA and NMA regimens used at our institu-
tion have been described previously [9-11]. In brief,
the patients undergoing MA related or unrelated do-
nor HCT received a regimen consisting of total body
irradiation (TBI) and cyclophosphamide (Cy; n 5
30), whereas the recipients ofMA umbilical cord blood
HCT received TBI, Cy, and fludarabine (Flu; n5 55).
The NMA regimen (n 5 61), which was common for
all donor types, comprised TBI, Cy, and Flu. The pre-parative regimen for patients with Fanconi anemia
(FA; n 5 17) included Cy, Flu, and antithymocyte
globulin (ATG). Other conditioning regimens were
used in the remaining 17 patients (9%).
Our GVHD prophylaxis and treatment regimens
also have been described previously [11,12]. All
patients received GVHD prophylaxis with Cy (from
day23 to at least day1100), with trough levels main-
tained at 200-400 ng/mL and either methotrexate
(MTX; in MA related and unrelated donor recipients)
or mycophenolate mofetil (MMF; in MA umbilical
cord blood and all NMA HCT recipients).Study Definitions
Disease risk was classified as standard risk or high
risk. Standard-risk disease included acute leukemia in
first complete remission (CR1), chronic myelogenous
leukemia (CML) in first chronic phase (CP1), myelo-
dysplastic syndrome (MDS; refractory anemia only),
and nonmalignant hematologic disorders. All other di-
agnoses were categorized as high-risk disease.
Hypertension was defined according to the
National Heart, Lung and Blood Institute’s Joint
National Committee’s criteria for adults [13]. Patients
with a systolic blood pressure$ 140mmHg and/or di-
astolic blood pressure $ 90 mm Hg or receiving
treatment for hypertension were classified as having
hypertension. For children, the National Heart,
Lung and Blood Institute’s Working Group on High
Blood Pressure in Children and Adolescents, defini-
tion for hypertension was used. The diagnosis is based
on blood pressure percentile, and hypertension is de-
fined as average systolic and/or diastolic blood pres-
sure $95th percentile for sex, age, and height [14].
The American Diabetes Association’s criteria were
used to define diabetes, and included patients with
a fasting plasma glucose level$ 126 mg/dL or a casual
plasma glucose level $ 200 mg/dL or receiving treat-
ment for diabetes mellitus [15].
Patients not receiving active treatment were re-
quired to have 2 abnormal evaluations (blood pressure
or plasma glucose) before they could be classified as
hypertensive or diabetic; the first abnormal evaluation
was considered the date of onset. Treatment of hyper-
tension and diabetes was not dictated by specific
protocols, and initiation and discontinuation of ther-
apy and choice of therapy was at the discretion of the
transplantation physician.
Body mass index (BMI) was calculated using the
formula BMI 5 weight (kg) / [height (m)]2. Centers
for Disease Control and Prevention’s criteria were
used to categorize BMI [16]. For adults (aged $ 20
years), BMI \ 18.5 was considered underweight,
BMI 18.5-24.9 was normal, BMI 25.0-29.9 was over-
weight, and BMI $ 30.0 was obese. For children
(aged 2-19 years), a BMI-for-age growth chart was
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was underweight, 5th-85th percentile was normal,
85th-95th percentile was overweight, and . 95th per-
centile was obese.
Cumulative prednisone dose (or the equivalent
for other corticosteroids) was estimated by chart re-
view. For this analysis, exposure to prednisone was
categorized as none, cumulative dose # 0.25 mg/
kg/day, or cumulative dose . 0.25 mg/kg/day. For
comparison, a daily prednisone dose of 0.25 mg/kg
in an adult weighing 60 kg given for 1 year would
correspond to a total cumulative prednisone dose
of 5400 mg.Statistical Analysis
The primary objective of this study was to describe
the natural history of hypertension and diabetes
among allogeneic HCT survivors who had survived
until 1 year post-HCT and to examine risk factors
that may predict the persistence of these disorders
beyond 2 years post-HCT. We chose the 2-year time
point for our analysis because this allowed for com-
plete ascertainment of events (onset or resolution of
hypertension and diabetes) in our study cohort. At
our transplantation center, all patients are followed
for at least 2 years post-HCT.
Patient and transplant characteristics were
compared using the c2, Fisher exact, or Wilcoxon
rank-sum test as appropriate. Overall survival (OS)
was determined using the Kaplan-Meier method. Cu-
mulative incidence estimates were obtained where
applicable, and death was considered a competing
risk. Multivariate logistic regression analysis was
performed to evaluate risk factors for development of
hypertension and diabetes post-HCT and for their
persistence at 2 years post-HCT. The following
variables were considered for both analyses: age, sex,
BMI (at HCT and at 2 years post-HCT), conditioning
regimen intensity, history of hypertension or diabetes
before HCT, renal failure (glomerular filtration rate
\ 60 mL/min/1.73 m2 at any time within 2 years
post-HCT), CsA exposure, and prednisone (or equiv-
alent) exposure. Because prednisone use was highly
correlated with aGVHD and cGVHD, the latter
were not included in the models. SAS version 9.1
(SAS Institute, Cary, NC) was used for all analyses.
All P values are 2-sided.RESULTS
Patients
A total of 180 HCT recipients (106 adult patients
and 74 pediatric patients) met the study inclusion
criteria. Patient-, disease-, and transplant-related char-
acteristics are summarized in Table 1. The probabilityof OS at 2 years post-HCT was 83% (95% confidence
interval [CI], 78%-88%) for the whole cohort, 76%
(95% CI, 68%-84%) for adult recipients, and 92%
(95% CI, 86%-98%) for pediatric recipients. In the
24 patients who died between 1 and 2 years post-HCT,
the most common cause of death was disease recur-
rence (50%), followed byGVHD (17%) and infections
(17%).GVHD and Exposure to CsA and Prednisone
Table 2 describes GVHD characteristics and
details of exposure to CsA and prednisone within the
first 2 years post-HCT. Compared with the pediatric
HCT recipients, the adult recipients had a higher fre-
quency of both aGVHD (61% vs 32%; P\ .01) and
cGVHD (44% vs 10%; P\ .01). Adults were more
likely to be exposed to CsA for prophylaxis or treat-
ment of GVHD (98% vs 84%; P \ .01), but were
less likely to have used CsA for an extended period
(. 6 months in 49% vs 74%; P\ .01). However, the
proportion receiving CsA therapy at 2 years post-
HCT was similar in the adult and pediatric recipients
(12% vs 20%; P 5 .15).
Prednisone was used to treat GVHD in 105
patients (58%), who received a median cumulative
prednisone dose of 3450 mg (range, 825-12,000 mg).
The rate of prednisone use for treating GVHD was
comparable in adults and children (63% vs 51%;
P 5 .11); however, adult recipients had a longer dura-
tion of exposure to prednisone (. 12months in 36% vs
20%; P 5 .02) and were more likely to continue pred-
nisone beyond 2 years post-HCT (30% vs 16%;
P 5 .03). But, pediatric recipients more frequently re-
ceived a higher cumulative dose (. 0.25 mg/kg/day) of
prednisone (34% vs 5%; P\ .01).Hypertension after Allogeneic HCT
The overall prevalence of hypertension within the
first 2 years post-HCTwas 70% (95%CI, 63%-77%)
and was similar in adults and children (68% vs 73%;
P 5 .47) (Table 3 and Figure 1). The majority of
patients with post-HCT hypertension (89%) were
receiving drug therapy for hypertension. New-onset
hypertension occurred during this period in 61% of
patients at a median of 1 month (range, 1-18 months)
post-HCT. Of these 109 patients with new-onset
hypertension, 88 experienced onset within 4 weeks
of initiating CsA therapy. In multivariate analysis,
CsA exposure at any time post-HCT was the sole fac-
tor predictive for development of new-onset hyper-
tension within the first 2-years post-HCT (relative
risk, 1.6; 95% CI, 1.1-2.5; P 5 .03 vs patients who
did not receive CsA).
Of the 126 patients with post-HCT hypertension,
109 survived until 2 years post-HCT; among these,
Table 1. Patient, disease, and transplant characteristics
Characteristics All patients Adult patients (age $ 18 years) Pediatric patients (age < 18 years)
Total patients, n 180 106 74
Median age, years (range) 27 (0.2-69) 48 (19-69) 8 (0.2-17)
Sex, n (%)
Male 102 (57%) 62 (59%) 40 (54%)
Female 78 (43%) 44 (42%) 34 (46%)
Hypertension pre-HCT, n (%) 17 (9%) 13 (12%) 4 (5%)
Diabetes mellitus pre-HCT, n (%) 24 (13%) 19(18%) 5 (7%)
History of smoking pre-HCT, n (%)
Yes 35 (19%) 33 (31%) 2 (3%)
No 83 (46%) 63 (59%) 20 (27%)
Unknown 62 (34%) 10 (9%) 52 (70%)
BMI at HCT, n (%)
Underweight 7 (4%) 2 (2%) 5 (7%)
Normal weight 75 (42%) 37 (35%) 38 (51%)
Overweight 51 (28%) 38 (36%) 13 (18%)
Obese 34 (19%) 29 (27%) 5 (7%)
Not evaluable (age < 2 years) 13 (7%) - 13 (18%)
Karnofsky/Lansky score at HCT, n (%)
90-100 149 (83%) 85 (80%) 64 (86%)
<90 22 (12%) 14 (13%) 8 (11%)
Missing 9 (5%) 7 (6%) 2 (3%)
Diagnosis, n (%)
Acute myelogenous leukemia 31 (17%) 22 (21%) 9 (12%)
Acute lymphoblastic leukemia 41 (23%) 28 (26%) 13 (18%)
Myelodysplastic syndrome 12 (7%) 9 (9%) 3 (4%)
Chronic myelogenous leukemia 13 (7%) 8 (8%) 5 (7%)
Chronic lymphocytic leukemia 9 (5%) 9 (9%) 0
Non-Hodgkin lymphoma 22 (12%) 21 (20%) 1 (1%)
Fanconi’s anemia 17 (9%) 0 17 (23%)
Aplastic anemia 8 (4%) 4 (4%) 4 (5%)
Inherited disorders of metabolism 17 (9%) 0 17 (23%)
Other 10 (6%) 5 (5%) 5 (7%)
Disease risk, n (%)*
Standard 99 (55%) 45 (43%) 54 (73%)
High 91 (45%) 61 (57%) 20 (27%)
Donor type, n (%)
Related donor 63 (35%) 45 (43%) 18 (24%)
Unrelated donor 117 (65%) 61 (57%) 56 (76%)
Conditioning regimen, n (%)
Myeloablative 119 (66%) 49 (46%) 70 (95%)
Nonmyeloablative 61 (33%) 57 (54%) 4 (5%)
Graft source, n (%)
Bone marrow 35 (19%) 6 (6%) 29 (39%)
Peripheral blood stem cells 50 (28%) 45 (43%) 5 (7%)
Umbilical cord blood
Single unit 35 (19%) 3 (3%) 32 (43%)
Two units 60 (33%) 52 (49%) 8 (11%)
HLA match status, n (%)†
6/6 81 (45%) 50 (47%) 31 (42%)
5/6 38 (21%) 8 (8%) 30 (41%)
4/6 61 (33%) 48 (45%) 13 (18%)
CMV serostatus, n (%)
Positive (donor and/or recipient) 88 (49%) 52 (49%) 36 (49%)
Negative (donor and recipient) 92 (51%) 54 (51%) 38 (51%)
Median follow-up, months (range) 41 (25-61) 43 (25-61) 40 (25-61)
Follow-up status, n (%)
Alive at 1 year 180 (100%) 106 (100%) 74 (100%)
Alive at 2 years 156 (87%) 86 (81%) 70 (95%)
HCT indicates hematopoietic cell transplantation; BMI, body mass index; CMV, cytomegalovirus.
*Standard risk disease included acute leukemia in first complete remission, chronic myelogenous leukemia in first chronic phase, myelodysplastic syn-
drome (refractory anemia only), and nonmalignant hematologic disorders; all other diagnoses were categorized as high-risk disease.
†Worst match for double umbilical cord blood transplantation.
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(Figure 2). Hypertension had resolved in the other
66% of patients. Patients with persistent hyperten-
sion were more likely to have had a history of
hypertension before undergoing HCT (Table 4). Inmultivariate analysis, the relative risk of persistent hy-
pertension at 2 years was 3.1 (95% CI, 1.1-8.3;
P 5 .03) in patients with pre-HCT hypertension
compared with those who were normotensive before
HCT.
Table 2. GVHD and its management within the first 2 years post-HCT
All patients Adult patients (age $ 18 years) Pediatric patients (age < 18 years)
Total patients, n 180 106 74
Acute GVHD (grade II-IV), n (%) 89 (49%) 65 (61%) 24 (32%)
Median time to onset, days (range) 34 (12-86) 33 (15-86) 35 (12-78)
Chronic GVHD, n (%) 54 (30%) 47 (44%) 7 (10%)
Median time to onset, months (range) 5 (3-22) 5 (3-22) 5 (3-9)
Cyclosporine use, n (%)* 166 (92%) 104 (98%) 62 (84%)
Median duration of use, months (range) 9 (3-24) 6 (3-24) 12 (3-24)
Duration of use, n
< 6 months 73 54 19
6-12 months 53 27 26
> 12 months 40 23 17
Receiving cyclosporine at 2 years, n 28 13 15
Prednisone use, n (%)† 105 (58%) 67 (63%) 38 (51%)
Median duration of therapy, months (range) 11 (2-24) 13 (4-24) 8 (2-24)
Duration of therapy, n
# 12 months 55 29 23
> 12 months 50 38 15
Receiving prednisone at 2 years, n 44 32 12
Cumulative dose of prednisone
Median dose, mg/kg/day (range) 0.2 (0.04-3.7) 0.1 (0.04-0.7) 0.4 (0.1-3.7)
Cumulative dose, n
# 0.25 mg/kg/day 75 62 13
> 0.25 mg/kg/day 30 5 25
HCT indicates hematopoietic cell transplantation; GVHD, graft-versus-host disease.
All patients included in this study had survived at for at least 1 year post-HCT.
*For prophylaxis or treatment of GVHD.
†For treatment of acute or chronic GVHD.
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The overall prevalence of diabetes within the first 2
years post-HCT was 30% (95% CI, 23%-37%)
(Table 3 and Figure 1). The prevalence was compara-
ble in the adult and pediatric recipients (30% vs 30%;
P 5 .95). Some 76% of patients with diabetes had
received insulin therapy post-HCT.New-onset diabe-
tes occurred in 17% of patients at a median of 1 month
(range, 1-12 months) post-HCT. In these 30 patients
with new-onset diabetes, 22 experienced onset within
4 weeks of initiating corticosteroid therapy for
GVHD. In multivariate analysis, prednisone exposure
was the only risk factor significantly associated withTable 3. Hypertension and diabetes mellitus in the first 2 years po
All patients Ad
Total patients, n 180
Hypertension post-HCT
Prevalence, n (%) 126 (70%)
New-onset hypertension, n (%) 109 (61%)
Median time of onset, months (range)* 1 (1-18)
Hypertension resolved by 2 years, n 87
Median duration, months (range)† 5 (1-24)
Diabetes post-HCT
Prevalence, n (%) 54 (30%)
New-onset diabetes, n (%) 30 (17%)
Median time of onset, months (range)* 1 (1-12)
Diabetes resolved by 2 years, n 32
Median duration, months (range)† 3 (2-17)
HCT indicates hematopoietic cell transplantation.
All patients included in this study had survived at for at least 1 year post-HCT
*From the date of HCT
†From the date of onset of hypertension or diabetesthe development of new-onset diabetes within the first
2 years post-HCT. Compared with patients with no
prednisone exposure, the relative risk of diabetes was
1.9 (95% CI, 1.0-3.7; P 5 .05) in patients receiving
a cumulative prednisone dose # 0.25 mg/kg/day and
3.6 (95% CI, 1.7-7.5; P\ .01) in patients receiving
a cumulative prednisone dose of 0.25 mg/kg/day.
Of the 54 patients with post-HCTdiabetes, 47 sur-
vived until 2 years post-HCT. Persistent diabetes was
present in 15 of these patients (32%), whereas it had re-
solved in 32 patients (68%) by the 2-year visit (Fig-
ure 2). Compared with patients with resolved
diabetes, those with persistent diabetes were morest-HCT
ult patients (age $ 18 years) Pediatric patients (age < 18 years)
106 74
72 (68%) 54 (73%)
59 (56%) 50 (68%)
1 (1-18) 1 (1-18)
51 36
5 (1-20) 5 (2-24)
32 (30%) 22 (30%)
13 (12%) 17 (23%)
1 (1-9) 1 (1-12)
18 14
3 (2-17) 3 (2-12)
Figure 1. Prevalence of hypertension anddiabeteswithin the first 2 years
post-HCT by prednisone (or equivalent) exposure. Our study cohort
comprised of patients who had survived for >1 year after transplantation.
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exposure to higher cumulative doses of prednisone
(Table 4). Both of these factors also significantly influ-
enced the risk of persistent diabetes at 2 years in
multivariate analysis; the relative risk was 5.7 (95%
CI, 1.5-21.2; P 5 .01 vs no history) in patients with
a history of pre-HCT diabetes and 4.1 (95% CI,
1.0-18.2; P 5 .05 vs no prednisone) in patients receiv-
ing a cumulative prednisone dose of . 0.25 mg/kg/
day. Exposure to a cumulative prednisone dose
# 0.25 mg/kg/day did not increase these risks (relative
risk, 1.3; 95% CI, 0.3-5.8; P5 .76).Figure 2. Prevalence of persistent hypertension and diabetes at 2-years
post-HCT by prednisone (or equivalent) exposure. Our study cohort
comprised of patients who had survived for >1 year after transplantation.DISCUSSION
Ourdata provide important insights into thenatural
history of early-onset hypertension and diabetes in allo-
geneic HCT recipients. Both diseases are highly preva-
lent (hypertension, 70%; diabetes, 30%) in the first 2
years post-HCT. Inpatientswith incidenthypertension
and diabetes, onset typically occurs very early post-
HCT (median time to onset, 1 month for both disor-
ders).Onset of hypertension usually corresponds to ini-
tiation of CsA therapy, and onset of diabetes frequently
occurs soon after initiation of corticosteroid therapy for
GVHD. Both hypertension and diabetes subsequently
resolve in a large proportion of HCT recipients, and
their overall duration is typically short in these patients
(median duration, 5 months for hypertension and 3
months for diabetes). As can be expected, a history of
hypertension and diabetes before HCT increases the
risk after HCT, and both disorders are less likely to re-
solve with long-term follow-up in these patients. Expo-
sure to CsA is associated with post-HCT hypertension.
Exposure to high-dose prednisone (or equivalent) is as-
sociated with post-HCT diabetes and its persistence
through 2 years post-HCT.
The prevalence of early hypertension and diabetes
in allogeneic HCT recipients has been reported, par-
ticularly in clinical trials comparing the use of
tacrolimus and CsA for GVHDprophylaxis. But, these
studies could not address the clinical course post-
HCT, especially given that some of the risk factors
for their development may change and even resolve
over time. Hypertension has been reported in 21%-
63% of patients; hyperglycemia requiring treatment,
in 10%-70% [17-20]. At least one study reported
a significantly lower risk of hypertension with tacroli-
mus [19], although this was not confirmed in other
studies. Although the risk factors and natural history
of hypertension and diabetes occurring in the early
post-HCT period among HCT recipients have not
yet been well described, certain generalizations can
be extrapolated from experience in solid organ
transplant recipients. Calcineurin inhibitor–induced
hypertension occurs very frequently in recipients of
heart, lung, liver, and kidney transplantation, with
reported prevalences ranging from 65% to 100%
[21-23]. Its origin is most likely multifactorial, includ-
ing renal vasoconstriction, increased systemic vascular
resistance, increased sympathetic nervous tone, and
activation of the renin-angiotensin system. Hyperten-
sion is seen more frequently in patients receiving
CsA-based immunosuppression compared with those
receiving tacrolimus-based regimens. In general, corti-
costeroids are not considered a risk factor for hyperten-
sion, although high-dose corticosteroid therapy can
temporarily increase this risk [21,24]. Sirolimus and
MMF have not been observed to have a hypertensive
effect. In contrast to solid organ transplant recipients,
Table 4. Comparison of patients with persistent and resolved hypertension or diabetes at 2 years post-HCT
Hypertension at 2 years* Diabetes at 2 years†
Resolved Persistent P‡ Resolved Persistent P‡
Total patients, n 72 37 28 19
Median age, years (range) 23 (0.6-68) 21 (1-59) .69 23 (1-57) 22 (2-59) .51
Male, n (%) 40 (56%) 23 (62%) .51 18 (64%) 10 (53%) .42
Pre-HCT hypertension, n (%) 4 (6%) 7 (19%) .02 6 (21%) 9 (47%) .06
Pre-HCT diabetes, n (%) 11 (15%) 5 (14%) .81 1 (4%) 6 (32%) < .01
Myeloablative conditioning, n (%) 54 (75%) 26 (70%) .60 23 (82%) 14 (74%) .49
Renal failure post-HCT, n (%)§ 27 (38%) 20 (54%) .09 13 (46%) 12 (63%) .26
Cyclosporine use > 12 months, n (%) 13 (18%) 8 (22%) .65 12 (43%) 13 (68%) .08
Cumulative prednisone dose > 0.25 mg/kg/day, n (%) 17 (24%) 7 (19%) .58 5 (18%) 9 (47%) .02
HCT indicates hematopoietic cell transplantation.
All patients included in this study had survived at for at least 1 year post-HCT.
*Excludes 17 patients (15 resolved, 2 persistent) with prevalent hypertension who died before the 2-year post-HCTanniversary time point.
†Excludes 7 patients (4 resolved, 3 persistent) with prevalent diabetes who died before the 2-year post-HCTanniversary time point.
‡Using the c2 test, Fisher’s exact test, or Wilcoxon’s rank-sum test, as appropriate.
§Defined as calculated glomerular filtration rate <60 mL/min/1.73 m2 at any time within the first 2 years post-HCT.
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they do not have active GVHD. Although there are
no data on the long-term effects of calcineurin inhibi-
tors, we speculate that these inhibitors’ effects on the
renovascular system are reversible, given the large
number of patients in our study who were able to dis-
continue therapy for hypertension.
As with hypertension, we have only limited knowl-
edge of the risk factors, natural history, and impact of
hyperglycemia and diabetes occurring early post-
HCT. One study found that hyperglycemia was
commonly associated with the use of total parenteral
nutrition in HCT recipients and was a risk factor for
infections, blood product support, and delayed
granulocyte and platelet engraftment [25]. In a recent
retrospective analysis by Hammer et al. [26], at least
1 episode of hyperglycemia (defined as blood glucose
.150 mg/dL) occurred in 93% of 1175 adult alloge-
neic HCT recipients within the first 100 days after
transplantation. Hyperglycemia and increased glucose
variability led to a significantly higher risk of infection
and nonrelapse mortality (NRM). In solid organ trans-
plant recipients, tacrolimus has been reported to be
a major risk factor for new-onset diabetes, with CsA-
containing immunosuppressive regimens associated
with lower risk [27-29]. Other important risk factors
for impaired glucose tolerance in this population
include older recipient age, obesity, and preexisting di-
abetes [28]. The risk of post-HCT diabetes after solid
organ transplantation also is increased by exposure to
higher doses of corticosteroids, and glucose tolerance
usually improves with tapering of corticosteroid dose
[30-32]. In our cohort of HCT recipients, we also
identified exposure to higher doses of prednisone as
one of the most important risk factors for the develop-
ment and persistence of diabetes.
Our studyhas the usual limitationsof a retrospective
cohort studydesign.Tominimizemisclassification, def-
initions of hypertension and diabetes were establisheda priori, and patients were required to have at least
2 abnormal measurements. There were no specific
guidelines for management; in particular, patients with
hypertension may have continued therapy despite its
resolution. Nonetheless, our observations are very rele-
vant, because they reflect routine clinical practice. We
did not examine the persistence of hypertension and
diabetes beyond 2 years post-HCT. Because patients
without cGVHD are discharged to their referring phy-
sicians at 2 years, follow-up beyond this time point
would have led to a disproportionate number of patients
with cGVHDin the cohort, and thenwewould have not
been able to identify those patients without GVHD in
whom hypertension and diabetes had resolved. The
duration of hypertension and diabetes was relatively
short (\6 months) in patients in whom these disorders
improved, and those patients with persistent hyperten-
sion and diabetes at 2 years post-HCT can be expected
to have a low likelihood of subsequent resolution.
Finally, we had no information regarding pre-HCT
treatment exposures, which also may contribute to the
risk of post-HCT hypertension and diabetes.
In conclusion, hypertension and diabetes are com-
mon early complications in both adult and pediatric
HCT recipients. Exposure to CsA increases the risk of
hypertension, whereas exposure to high-dose cortico-
steroids increases the risk of diabetes. That both hyper-
tension and diabetes resolve in the majority of HCT
survivors is reassuring; however, hypertension and dia-
betes can persist long term in some HCT survivors,
and aggressive screening and treatment strategies may
be needed to prevent late cardiovascular complications
in these patients. Further studies are needed to address
some important unanswered questions, including the
impact of limited-duration hypertension and glucose
intolerance on the risk of cardiac and renal late effects
and the optimal therapy for these complications.
Financial disclosure: The authors have nothing to
disclose.
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